Cannabis Use Disorder in 2026: Signs, Withdrawal, Treatment, and What Changed
By Chris Beerman, MSW, LCSW, CADC · Chicago Addiction Therapy · September 2026
Cannabis use disorder is a medical condition in which cannabis use becomes hard to control and continues despite real consequences. In 2025, an estimated 19.3 million Americans age 12 and older — 6.7 percent — met criteria for it in the past year. That is the headline number. It is also the least interesting thing about it.
The more interesting thing is that cannabis use disorder in 2026 exists in an environment that did not exist twenty-five years ago. Cannabis is legal for adults in Illinois and in 23 other states. Illinois dispensaries sold roughly $1.5 billion of it in 2025 — more than 52 million individual products. The products themselves have changed: high-THC flower, concentrates, vape cartridges, edibles, drinks. Daily and near-daily use has risen more than fifteen-fold since the early 1990s. And the diagnosis itself was rewritten in 2013.
So the question people actually bring me is rarely "is weed addictive?" — the answer is yes, and most people know it. The questions are more specific: Is my use the kind that's a problem? What's normal now? What happens if I stop? Does anything actually help?
This guide is my attempt to answer those questions the way I would in a first session — with the evidence, and without either panic or reassurance the evidence doesn't support.
A note on what this is. This article is education from a licensed clinician, not a diagnosis or individualized medical advice. If you want a private read on your own use before you read further, the free Cannabis Use Test on this site takes two minutes and scores itself in your browser.
The short version
Cannabis use disorder — CUD — is diagnosed when cannabis use causes clinically significant impairment or distress and a person meets at least two of eleven criteria in a twelve-month period. Two or three criteria is mild; four or five is moderate; six or more is severe.
Three things follow from that definition, and each one gets misunderstood:
Using cannabis is not the same as having CUD. Plenty of people use it without meeting criteria.
Using daily is not, by itself, a diagnosis — but frequency is the single strongest risk marker we have, and daily use is where disorders develop.
You don't have to look like an addict. Mild CUD is still CUD. Someone with a career, a mortgage and a nightly habit they've tried three times to break can meet criteria without anything in their life visibly falling apart.
How common is it, really?
The 2025 National Survey on Drug Use and Health — the federal government's main survey, released in July 2026 — puts past-year cannabis use disorder at:
All Americans 12 and older: 6.7 percent, about 19.3 million people
Ages 18–25: 14.1 percent, about 5.1 million — the highest rate of any group
Ages 26 and older: 5.7 percent, about 13.1 million — the largest number of people, because the group is so much bigger
Ages 12–17: 4.4 percent, about 1.1 million
Two trends underneath those numbers matter more than the numbers themselves.
First, the adult rate is climbing. Among people 26 and older, past-year CUD rose from 4.7 percent in 2021 to 5.7 percent in 2025. A 2026 JAMA Psychiatry analysis of the same survey found that between 2021 and 2024, past-year CUD among adult men rose from 7.3 to 9.3 percent and among adult women from 4.5 to 5.6 percent — with the increases in moderate-to-severe disorder concentrated among men over 35 and women over 21. The stereotype of cannabis addiction as a college problem is about a decade out of date.
Second, it is not a straight line. The 12-and-older rate was 7.1 percent in 2024 and dipped to 6.7 in 2025. Prevalence is substantially higher than at the start of the current survey series, and individual years move around. Anyone showing you a smooth upward curve is smoothing it.
The Illinois picture
Illinois legalized adult-use cannabis on January 1, 2020. Five years later there is a licensed dispensary within a short drive of nearly everyone in the Chicago area, and the state's own figures put 2025 adult-use sales at about $1.5 billion. There is no Illinois-specific CUD prevalence estimate I would put my name to — the state-level survey samples are too small — so I use the national figures and assume Illinois is not an exception. Nothing about the Illinois market suggests it would be.
Is cannabis addictive?
Yes. Cannabis acts on the brain systems that handle reward, learning and motivation, and repeated exposure produces tolerance, withdrawal, craving and, in some people, a compulsive pattern of use. That is the definition of an addictive drug.
What it does not have is a single, timeless probability of addiction. You will see "about 3 in 10 people who use cannabis have cannabis use disorder" — that is the CDC's current summary, and it is a reasonable one. A 2020 meta-analysis of the epidemiologic studies put the pooled figure at about 22 percent of people who have ever used, with dependence closer to 13 percent and the risk among young people using regularly around one in three.
The reason the number moves is that risk isn't a property of the plant. It's a property of the exposure: how early you started, how often you use, what you use, and what you're using it for.
The clearest single finding on this comes from a 2022 pooled analysis of six prospective studies. Compared with not using, the risk of developing CUD rose steadily across yearly, monthly and weekly use, and was highest — roughly one in three — among daily users. That is a dose-response relationship, and it is the reason frequency is the first thing I ask about.
What changed in 25 years
The reason today's cannabis use disorder can't be understood with assumptions from 2001 is that the drug changed, the pattern changed, and the diagnosis changed. Briefly:
Potency. DEA seizure data show average THC in plant material rising from about 4 percent in 1995 to about 12 percent in 2014, with CBD falling over the same period. Later research the CDC cites put the average at 9 percent in 2008 and 17 percent in 2017; a study of products sold in three adult-use states found an average around 22 percent, with a range up to 45. And that is flower. Concentrates — dabs, wax, the oil in most vape cartridges — commonly average 60 to 70 percent THC, with some products approaching 90. A 2025 systematic review in Annals of Internal Medicine of 99 studies and more than 221,000 participants found high-concentration THC products consistently associated with worse outcomes for both CUD and psychosis. Its authors also noted that almost every included study had a meaningful risk of bias, which is the honest caveat: potency matters, and the research on exactly how much is still catching up.
Frequency. An analysis of fifty years of national survey data, published in Addiction in 2024, found that per-capita daily or near-daily cannabis use rose fifteen-fold between 1992 and 2022. In 1992, daily drinkers outnumbered daily cannabis users about ten to one. In 2022, for the first time, it flipped: 17.7 million Americans reported daily or near-daily cannabis use against 14.7 million daily or near-daily drinkers. More people still drink than use cannabis. But among people who do use cannabis, the daily pattern is now the common one — 42 percent of past-month users, versus 11 percent of drinkers.
Products. Cannabis was a smoked plant. It is now smoked, vaped, dabbed, eaten and drunk, often by the same person in the same week. In 2025, 37 percent of current users age 12 and up reported vaping cannabis in the past month — 54 percent of users aged 18 to 25. A 2026 analysis in Addiction found more than half of past-year users using multiple modes, and CUD roughly four times as prevalent among multimodal users as among people who used edibles alone. That's observational — people with a developing problem may reach for more modes, rather than the modes causing the problem — but it changes the questions worth asking. "Do you smoke weed?" is no longer the question. How many days a month, how many times a day, what form, what strength, what time of day, and what happens when you stop — that's the assessment.
The law. In 2012 no state had legal adult-use sales. Today 24 states and the District of Columbia do. In April 2026 the federal government moved FDA-approved cannabis products and products sold under qualifying state medical-cannabis licenses into Schedule III, while a broader proceeding on rescheduling marijuana continued. None of this bears on whether an individual has a disorder. Alcohol is legal, regulated, taxed and sold on every block in Chicago, and alcohol use disorder is not a controversial diagnosis.
The diagnosis. In 2013 the DSM-5 replaced the separate categories of "abuse" and "dependence" with a single cannabis use disorder graded mild to severe. Craving was added as a criterion; legal problems were dropped; and cannabis withdrawal was formally recognized. This was clinically the right move. It also means you cannot lay 2001 prevalence figures next to 2025 ones and read a trend off them — the definitions and the survey methods both changed. The honest statement is: within comparable data, cannabis use and CUD have risen substantially over the last twenty-five years, and the exact multiple is not knowable.
Did legalization cause this?
Partly, probably — and it is not one thing. Legalization changes availability, price, potency, marketing, social acceptance and perceived risk, and those don't change uniformly.
The best evidence: a national study covering 2008–2016 found recreational legalization associated with increased adult use and small increases in CUD among adults 26 and older. A study of the Veterans Health Administration found CUD rising in every group of states between 2005 and 2019 — legal and not — with legalization explaining only a modest share of the increase. A 2025 analysis of 110 million insurance enrollees found medical-cannabis laws associated with a rise in diagnosed CUD but recreational laws with no significant change in CUD, though both were associated with more cannabis poisonings. And a 2026 review in Lancet Psychiatry concluded that commercialized legal markets — the U.S. and Canadian model — are associated with increased adult use and CUD, while decriminalization and tightly regulated non-commercial models mostly aren't. The type of policy, not the fact of legality, seems to be what matters.
For someone in a session, none of this is the point. Cannabis being legal in Illinois has exactly as much bearing on whether your use is a problem as bourbon being legal has on whether your drinking is.
What cannabis use disorder actually looks like
The eleven criteria fall into four groups. I'll give you the clinical version and then what it sounds like in a room.
Impaired control. Using more, or for longer, than you meant to. Wanting to cut down and repeatedly not managing it. Spending a lot of time getting it, using it, or recovering from it. Craving it.
Impairment. Repeatedly failing at work, school or home because of it. Continuing despite it causing problems in relationships. Giving up or cutting back activities that used to matter.
Risky use. Using in situations where being impaired is physically dangerous. Continuing despite knowing it is causing or worsening a physical or psychological problem.
Adaptation. Tolerance — needing more for the same effect. Withdrawal when you stop.
Two of those in a year is mild CUD. Here is what "two" often sounds like:
I decided I'd only use on weekends and I'm back to every night. I keep saying I'll take a tolerance break and I keep not starting it. The evening kind of organizes itself around it now. I don't take trips where I can't bring it. My partner says I'm not really there when I'm high, and I've started to think she's right. Mornings are foggy. I know it's making my anxiety worse, or at least not better. And when I did stop for a few days I couldn't sleep and I was miserable, and the second I used again all of that went away — which felt like proof I needed it.
No single sentence in that paragraph is a diagnosis. Together, they are exactly what clinicians mean by impaired control plus continued use despite consequences. And notice that the person describing it has a job, a partner and an evening routine. Nothing has collapsed. That is what most CUD looks like.
How much is too much?
There is no number of grams, joints or milligrams that defines the disorder. It's diagnosed from symptoms and impairment, not a consumption line. But frequency is the clearest risk indicator we have, and a 2026 study of adults aged 40 to 60 found that almost half of those using near-daily had CUD symptoms. So daily use is not a diagnosis, and it is not nothing. The better question than how much do I use is how much of my day, my coping, my sleep and my decisions now run through it.
"I can stop whenever I want"
Stopping for a few days does not rule out CUD. Neither does a good job, a good income or a stable relationship. The questions that actually discriminate: Have I repeatedly used more than I planned? Has cutting down been harder than I expected? Has my dose or potency crept up? Do I arrange things so I can use? Am I uncomfortable when I can't? Is it affecting attention, motivation, relationships, money? Am I using partly to avoid how I feel without it? Has someone close to me said something? The more of those that land, the more a real assessment is worth your time — and the Cannabis Use Test is the two-minute version of that assessment.
Cannabis withdrawal is real, and it is why most attempts to stop fail
For years cannabis withdrawal was waved off, mostly because it doesn't look like alcohol or benzodiazepine withdrawal — it won't put you in the hospital. But not dangerous and not real are different claims. A 2020 meta-analysis of 47 studies estimated that about 47 percent of regular users experience a withdrawal syndrome when they stop — higher among people in treatment, lower in general-population samples.
What it feels like: irritability, anxiety or restlessness, anger, trouble falling or staying asleep, vivid or unpleasant dreams, low mood, reduced appetite, and in some people physical discomfort — headaches, sweating, stomach upset.
When: it usually begins within the first day or two after stopping, peaks somewhere in days two to six, and mostly resolves within two to three weeks. Sleep disturbance and vivid dreams are the symptoms that linger, sometimes for several weeks in heavy users.
Why it matters clinically: it produces a very specific relapse loop. You stop. Two nights later you can't sleep, you're irritable and anxious, and you conclude that cannabis had been treating those problems all along. You use again. The symptoms vanish within minutes. That relief is a powerful lesson, and it is the wrong one — because a large part of what you just relieved was withdrawal that the cannabis itself created. This is the single most common reason I see people abandon an attempt to stop, and knowing the timeline in advance is the single most useful thing I can give someone before they try. Night three is a symptom you expected, not evidence you can't do this.
One thing it is not: persistent, severe vomiting is not ordinary withdrawal. Cannabinoid hyperemesis syndrome — cyclical nausea and vomiting in some long-term heavy users, associated with continued use rather than stopping — is a medical issue and should be evaluated as one.
And a caution that runs the other way: if you also drink heavily, don't assume the two behave alike. Alcohol withdrawal can be medically dangerous, and heavy drinkers should not stop abruptly without medical guidance. Cannabis and alcohol travel together often enough that it's worth taking the alcohol use test too if you're not sure where your drinking sits.
Cannabis, mood, sleep and psychosis
People use cannabis to manage anxiety, low mood, trauma symptoms, ADHD restlessness and insomnia. That is not a moral failing; it's a rational response to distress with a tool that works fast. The problem is that frequent, high-THC use tends to worsen several of those same conditions over time, and the relationship runs in both directions.
Sleep is the clearest example. Cannabis helps you fall asleep. Nightly use builds tolerance. Stopping produces rebound insomnia and vivid dreams for a week or two. You conclude you can't sleep without it. At that point the original sleep problem and the cannabis adaptation are tangled together, and untangling them is a clinical job — is there an underlying sleep disorder, an anxiety disorder, a medication effect, or is this mostly withdrawal? Often it's more than one.
Psychosis deserves its own sentence. Heavy, frequent, high-potency use is consistently associated with higher psychosis risk, particularly in people with other vulnerability. A 2022 systematic review in Lancet Psychiatry found higher-potency cannabis associated with increased risk of both psychosis and CUD. This does not mean cannabis causes schizophrenia in everyone who uses it. It means that paranoia, hallucinations, or losing contact with reality after using is not something to wait out, and high-THC concentrates deserve real caution.
The outcome I worry about most isn’t on the diagnostic list
Everything above is about the criteria. Here is what I see as a therapist that the criteria don’t capture well, and that I think is one of the most dangerous things cannabis does: it numbs the signal of boredom.
Boredom is not a flaw. It is information — the feeling that tells you the life you’re living has a gap in it, that you want something you don’t have yet, and that it’s time to go find out what. It is uncomfortable on purpose. That discomfort is what gets people to change jobs, call someone, sign up for the thing, leave the apartment.
Cannabis is remarkably good at turning that signal off — not the situation, the signal. The evening that would have felt restless feels fine. The weekend that would have nagged at you passes pleasantly. Nothing hurts, so nothing changes. And because nothing is visibly wrong, nobody intervenes, least of all the person using. Years can go by this way. Not in crisis, not falling apart — just not doing anything.
No screening score catches that, and it rarely shows up as a criterion. It shows up as a life that looks the same as it did five years ago and a person who can’t quite say why. If cannabis has made your boredom comfortable, the question worth asking is what the boredom was trying to tell you before it went quiet.
Medical cannabis and CUD are not mutually exclusive
A medical card does not immunize anyone against tolerance, withdrawal or loss of control — and a 2026 study of adults aged 40 to 60 is instructive here. Medical users initially showed more CUD symptoms than non-medical users. Once the researchers controlled for how often people used, the difference essentially disappeared. Frequency, not the label, was doing the work.
Some CUD criteria are harder to read under medical supervision — tolerance to a prescribed dose means something different from tolerance to a habit — and a clinician should interpret them in context. But the monitoring is the same as for any psychoactive medication: is the dose escalating, is there withdrawal, is control slipping, are there consequences. Cannabis can be helping with pain or sleep and be a disorder. Both things can be true at once, and the useful question isn't "does it help" but "taking the benefits and harms together, is this still under my control."
What actually helps
The good news is that cannabis use disorder is treatable. The frustrating news is that treatment science has not kept pace with the market.
There is no medication for it. As of 2026, no drug is FDA-approved for cannabis use disorder, and a 2025 Cochrane review of 37 randomized trials concluded that every pharmacotherapy studied so far should still be considered experimental. Medication is often appropriate for what travels with CUD — depression, anxiety, an actual sleep disorder — but that is treating the co-occurring condition, not the CUD.
Treatment is talk-based, and it works. The approaches with evidence behind them:
Cognitive behavioral therapy — identifying the situations, thoughts and states that lead to use, and building skills that do the job cannabis was doing: for stress, for boredom, for the transition out of the workday, for sleep. A 2025 meta-analysis of 22 randomized trials found CBT-based treatment substantially improved abstinence compared with control conditions, with the honest caveat that the trial literature is still small and the certainty of the evidence is low.
Motivational enhancement therapy — for people who are ambivalent rather than decided, which is most people. It works with the gap between what someone is doing and what they say they want, without lecturing.
Contingency management — concrete reinforcement for verified progress. A 2024 meta-analysis found it improves abstinence outcomes for CUD. It sounds gimmicky and it isn't.
In practice these get combined, and in practice the work is less about stopping than about replacing. Someone using nightly for five years has built their evening around it. Remove the cannabis and leave the evening unchanged and the cannabis comes back, because nothing else is doing that job.
You don't have to promise abstinence to start. Some people want to stop entirely. Others want to get off concentrates, stop daytime use, stop before driving, or just regain the ability to skip a night. Treatment can begin with the goal a person is willing to work toward. For severe CUD with repeated relapse or serious psychiatric complications, abstinence often turns out to be the clearer path — but making it the price of admission keeps people out of care.
Most people with CUD never get treatment. Not because they never see a doctor — most do. The gap is between screening and an actual conversation about it, and it is compounded by the belief, common among people with CUD, that they can handle it themselves. Sometimes that's true. The people it isn't true for have usually found out by the time they call me.
If you're not ready to quit
The only way to eliminate the risk is not to use. Short of that, the evidence points to a few things that reduce it:
Use less often. Frequency is the strongest risk factor. Moving off daily or near-daily use reduces exposure, tolerance and reinforcement more than any other single change.
Be careful with high-THC products. Concentrates and high-potency flower are where the CUD and psychosis associations are strongest.
Think in doses, not products. A small amount of 15 percent flower and a dab at 70 percent are not the same exposure.
Notice when it becomes the default. If cannabis is the answer to stress, boredom, anger, sadness and insomnia, that is five reinforcement schedules running at once. Building a second tool for any one of them helps.
Don't drive. Cannabis impairs reaction time and judgment, and frequent users are more likely to drive impaired.
Don't ignore withdrawal. Using primarily to make withdrawal go away is clinically meaningful on its own.
Reassess every six months. Has dose, frequency, potency or the reason for use changed? Escalation is obvious in hindsight and invisible day to day.
When to talk to someone
Consider talking to a clinician — a therapist who works with substance use, an addiction-medicine physician, a psychiatrist — when:
attempts to cut down keep failing
use is daily or near-daily and hard to interrupt
withdrawal keeps driving you back
it's affecting work, relationships or money
anxiety, depression, paranoia or other psychiatric symptoms are getting worse
tolerance is climbing fast
you're using with other substances in ways that worry you
you've driven or done something dangerous while impaired
use feels less like a choice than it used to
You don't need to hit bottom. Mild CUD is still CUD, and the pattern is easier to change at two criteria than at six.
If you're reading this about a partner, a parent or an adult child rather than yourself, the page for partners and family members covers what you can and can't do from the outside.
When it's an emergency. Ordinary cannabis withdrawal doesn't need an emergency room. Acute intoxication or a psychiatric reaction sometimes does: collapse, seizure, trouble breathing, inability to wake someone, dangerous confusion or agitation, severe psychotic symptoms, or any intent to harm oneself or others — call 911. For a suspected poisoning or excessive dose, Poison Control at 1-800-222-1222 gives individualized guidance. If you're in crisis, call or text 988.
Getting help in Illinois
Illinois residents can reach the state's helpline for substance use — free, confidential, 24 hours a day — at 833-234-6343 or helplineil.org. Illinois also funds substance-use treatment through its Division of Substance Use Prevention and Recovery for residents regardless of insurance. Nationally, SAMHSA's helpline is 1-800-662-HELP (4357).
If you'd rather start privately, take the free Cannabis Use Test. It's the CUDIT-R — the same eight-question screen the research above uses — scored on your device, with nothing sent anywhere.
And if you want to talk it through with someone who does this for a living: I'm a licensed clinical social worker and certified alcohol and drug counselor. I see adults in person in Logan Square and online throughout Illinois and Minnesota, for cannabis, alcohol, gambling and the things that travel with them. Cannabis is rarely the only thing on the table when someone reaches out, and it doesn't need to be. Schedule a free 15-minute consultation whenever you're ready.
Frequently asked questions
Is weed addictive? Yes. Cannabis can produce a clinically recognized use disorder with impaired control, craving, continued use despite consequences, tolerance and withdrawal.
Does smoking every day mean I'm addicted? Not automatically. Daily use is the strongest risk factor, and roughly one in three daily users develops CUD, but the diagnosis depends on symptoms and impairment, not frequency alone.
Can you get addicted to edibles or vapes? Yes. CUD follows THC exposure and behavior, not the delivery method. Vapes and concentrates deliver high THC with very little friction, which is part of why they matter.
Is medical marijuana addictive? It can be. Medical purpose doesn't remove the risk, and frequency of use predicts CUD better than the reason for it.
When does withdrawal start, and how long does it last? Usually within a day or two of stopping, peaking around days two to six, mostly resolving in two to three weeks. Sleep problems and vivid dreams can last longer after heavy use.
Is cannabis withdrawal dangerous? Not medically, for most healthy adults — unlike alcohol or benzodiazepine withdrawal. It is uncomfortable enough to end most quit attempts, and significant psychiatric symptoms during withdrawal deserve professional support.
Can a drug test diagnose it? No. A test shows exposure. CUD is diagnosed from a pattern of symptoms and consequences.
Is there a medication? Not yet. No drug is FDA-approved for cannabis use disorder. Treatment is behavioral — CBT, motivational enhancement and contingency management — and it works.
Do I have to go to rehab? Usually not. Most cannabis use disorder is treated outpatient. Level of care depends on severity, other substances, psychiatric symptoms and what has already been tried.
Has legalization made this worse? CUD has increased across the legalization era, especially among adults, and commercialized legal markets are associated with higher use and CUD. But use was rising before legalization and rose in states that never legalized. It is one driver among several.
The bottom line
Cannabis use disorder isn't new. The environment is. Twenty-five years ago cannabis was weaker, concentrates weren't a consumer category, daily use was uncommon, no state sold it legally, and psychiatry split the problem into "abuse" and "dependence." Today nearly twenty million Americans meet criteria in a given year, the daily pattern is the common one among users, and Illinois alone sells a billion and a half dollars of it annually.
None of that means cannabis is uniquely dangerous, and none of it means your use is a problem. What the research says, over and over, is simpler: frequency matters, potency matters, age of first use matters, and above all loss of control and consequences matter. The useful question isn't whether cannabis is good or bad. It's whether your use is still something you decide — or whether it has started making more of the decisions than you have.
If it's the second one, that's treatable, and it's treatable long before anything falls apart.
This article is general information from a licensed clinician, not medical advice, and not a substitute for an assessment. Cannabis use disorder can only be diagnosed by a clinician. If you are in immediate danger, call 911; in crisis, call or text 988.
Research and sources
Substance Abuse and Mental Health Services Administration. 2025 National Survey on Drug Use and Health: Annual National Report and Detailed Tables (released July 2026).
Han B, et al. Trends in the Prevalence and Severity of Alcohol and Cannabis Use Disorders Among US Adults. JAMA Psychiatry, 2026.
Centers for Disease Control and Prevention. Understanding Your Risk for Cannabis Use Disorder; Cannabis and Poisoning.
Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? Addictive Behaviors, 2020.
Robinson T, et al. Association of cannabis use frequency with cannabis use disorder. Drug and Alcohol Dependence, 2022.
Hasin DS, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 2015.
Caulkins JP. Changes in self-reported cannabis use in the United States from 1979 to 2022. Addiction, 2024.
ElSohly MA, et al. Changes in cannabis potency over the last two decades. Biological Psychiatry, 2016.
Rittiphairoj T, et al. High-Concentration Delta-9-THC Cannabis Products and Mental Health Outcomes: A Systematic Review. Annals of Internal Medicine, 2025.
Petrilli K, et al. Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry, 2022.
Baral A, et al. Associations between modes of cannabis use and cannabis use disorder. Addiction, 2026.
Terry-McElrath YM, Patrick ME. Cannabis use disorder risk among midlife adults reporting medical and nonmedical cannabis use, 2019–2024. Drug and Alcohol Dependence, 2026.
Cerdá M, et al. Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016. JAMA Psychiatry, 2020.
Hasin DS, et al. State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019. JAMA Psychiatry, 2023.
Jayawardhana J, et al. Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning. JAMA Psychiatry, 2025.
Freeman TP, et al. International cannabis policies and their association with cannabis use, cannabis use disorder, and other psychiatric disorders. Lancet Psychiatry, 2026.
Bahji A, et al. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Network Open, 2020.
Halicka M, et al. Effectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: systematic review and meta-analysis. Addiction, 2025.
Lima MG, Tardelli VS, Fidalgo TM. Contingency Management for Cannabis Use Disorder Treatment. European Addiction Research, 2024.
Spiga F, et al. Pharmacotherapies for cannabis use disorder. Cochrane Database of Systematic Reviews, 2025.
Hasin DS, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. American Journal of Psychiatry, 2013.
National Conference of State Legislatures. State Medical Cannabis Laws (adult-use count as of June 2025).
U.S. Department of Justice. Press release and Federal Register final rule on Schedule III placement, April 2026.
Illinois Department of Financial and Professional Regulation. Adult-use cannabis sales figures, calendar year 2025.
Adamson SJ, et al. An improved brief measure of cannabis misuse: the CUDIT-R. Drug and Alcohol Dependence, 2010.
Last evidence review: September 5, 2026.